SYRS - Syros Pharmaceuticals Stock Price, News & Analysis

$13.54 0.24 (1.80 %)
(As of 11/23/2017 03:40 PM ET)
Previous Close$13.30
Today's Range$12.91 - $13.65
52-Week Range$10.22 - $24.38
Volume123,000 shs
Average Volume92,234 shs
Market Capitalization$349.74 million
P/E RatioN/A
Dividend YieldN/A
Beta-3.33

About Syros Pharmaceuticals (NASDAQ:SYRS)

Syros Pharmaceuticals logoSyros Pharmaceuticals, Inc. is a biopharmaceutical company. The Company offers a gene control platform designed to analyze the unexploited region of deoxyribonucleic acid (DNA) in human disease tissue to identify and drug targets linked to genomically defined patient populations. The Company is focused on developing treatments for cancer and immune-mediated diseases and is building a pipeline of gene control medicines. The Company's drug programs include SY-1425 (retinoic acid receptor alpha (RARa) agonist) and SY-1365 (cyclin-dependent kinase 7 (CDK7) inhibitor). SY-1425 (tamibarotene) is an oral, potent and selective agonist, or activator, of the transcription factor RARa. SY-1365 is a small molecule inhibitor of the transcriptional kinase known as CDK7. The Company is using its platform to analyze gene expression programs across additional cancers, inflammatory diseases and other diseases to identify optimal points of therapeutic intervention in specific subsets of patients.


Industry, Sector and Symbol

Industry Biopharmaceuticals
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:SYRS
CUSIPN/A

Debt

Debt-to-Equity RatioN/A
Current Ratio9.01%
Quick Ratio9.01%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$320,000.00
Price / Sales1,112.82
Cash FlowN/A
Price / CashN/A
Book Value$2.99 per share
Price / Book4.53

Dividend

Annual DividendN/A
Dividend YieldN/A

Profitability

Trailing EPS($2.01)
Net Income$-47,740,000.00
Net MarginsN/A
Return on Equity-62.01%
Return on Assets-55.65%

Miscellaneous

Employees55
Outstanding Shares26,300,000

Frequently Asked Questions for Syros Pharmaceuticals (NASDAQ:SYRS)

What is Syros Pharmaceuticals' stock symbol?

Syros Pharmaceuticals trades on the NASDAQ under the ticker symbol "SYRS."

How were Syros Pharmaceuticals' earnings last quarter?

Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) released its quarterly earnings results on Wednesday, November, 8th. The company reported ($0.53) earnings per share (EPS) for the quarter, hitting the Thomson Reuters' consensus estimate of ($0.53). View Syros Pharmaceuticals' Earnings History.

Where is Syros Pharmaceuticals' stock going? Where will Syros Pharmaceuticals' stock price be in 2017?

7 equities research analysts have issued 1 year target prices for Syros Pharmaceuticals' shares. Their forecasts range from $15.00 to $33.00. On average, they anticipate Syros Pharmaceuticals' share price to reach $26.14 in the next twelve months. View Analyst Ratings for Syros Pharmaceuticals.

What are Wall Street analysts saying about Syros Pharmaceuticals stock?

Here are some recent quotes from research analysts about Syros Pharmaceuticals stock:

  • 1. According to Zacks Investment Research, "Syros Pharmaceuticals, Inc. is a biopharmaceutical company. It focuses on treatments for cancer and immune-mediated diseases as well as building a pipeline of gene control medicines. The company's product pipeline includes SY-1425, a selective RARa agonist for genomically defined subsets of patients with relapsed or refractory acute myeloid leukemia and relapsed high-risk myelodysplastic syndrome and SY-1365, a selective CDK7 inhibitor for acute leukemia which is in preclinical stage. Syros Pharmaceuticals, Inc. is based in Cambridge, Massachusetts. " (10/17/2017)
  • 2. Cann analysts commented, "Syros announced today that FDA has granted orphan drug designation to SY-1425 for the treatment of acute myeloid leukemia (AML). FDA’s Office of Orphan Drug Products grants orphan status to support development of medicines for the treatment of rare diseases that affect fewer than 200,000 people in the United States. Orphan drug designation may provide certain benefits, including a seven-year period of market exclusivity if the drug is approved, tax credits for qualified clinical trials and an exemption from FDA application fees." (8/21/2017)

Who are some of Syros Pharmaceuticals' key competitors?

Who are Syros Pharmaceuticals' key executives?

Syros Pharmaceuticals' management team includes the folowing people:

  • Peter Wirth, Independent Chairman of the Board (Age 66)
  • Nancy A. Simonian M.D., Principal Financial Officer, Director (Age 56)
  • Kyle D. Kuvalanka, Chief Operating Officer (Age 48)
  • Colleen DeSimone, Principal Accounting Officer (Age 47)
  • Eric R. Olson Ph.D., Chief Scientific Officer (Age 59)
  • Gerald E. Quirk Esq., Chief Legal Officer (Age 49)
  • David A. Roth M.D., Chief Medical Officer (Age 54)
  • Srinivas Akkaraju M.D., Ph.D., Director (Age 49)
  • Stephane Bancel, Independent Director (Age 44)
  • Marsha H. Fanucci, Independent Director (Age 63)

When did Syros Pharmaceuticals IPO?

(SYRS) raised $60 million in an initial public offering (IPO) on Thursday, June 30th 2016. The company issued 4,000,000 shares at a price of $14.00-$16.00 per share. Cowen and Company and Piper Jaffray served as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

Who owns Syros Pharmaceuticals stock?

Syros Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional shareholders include JPMorgan Chase & Co. (0.48%), Candriam Luxembourg S.C.A. (0.46%), Citadel Advisors LLC (0.25%), Schwab Charles Investment Management Inc. (0.16%), Bank of New York Mellon Corp (0.13%) and Trexquant Investment LP (0.07%). Company insiders that own Syros Pharmaceuticals stock include Colleen Elizabeth Desimone, Eric R Olson, Redmile Group, Llc, Richard A Young and Robert Nelsen. View Institutional Ownership Trends for Syros Pharmaceuticals.

Who bought Syros Pharmaceuticals stock? Who is buying Syros Pharmaceuticals stock?

Syros Pharmaceuticals' stock was bought by a variety of institutional investors in the last quarter, including Candriam Luxembourg S.C.A., Citadel Advisors LLC, Schwab Charles Investment Management Inc., Trexquant Investment LP, JPMorgan Chase & Co., GSA Capital Partners LLP, State Treasurer State of Michigan and Cubist Systematic Strategies LLC. Company insiders that have bought Syros Pharmaceuticals stock in the last two years include Redmile Group, Llc and Robert Nelsen. View Insider Buying and Selling for Syros Pharmaceuticals.

How do I buy Syros Pharmaceuticals stock?

Shares of Syros Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Syros Pharmaceuticals' stock price today?

One share of Syros Pharmaceuticals stock can currently be purchased for approximately $13.54.

How big of a company is Syros Pharmaceuticals?

Syros Pharmaceuticals has a market capitalization of $349.74 million and generates $320,000.00 in revenue each year. The company earns $-47,740,000.00 in net income (profit) each year or ($2.01) on an earnings per share basis. Syros Pharmaceuticals employs 55 workers across the globe.

How can I contact Syros Pharmaceuticals?

Syros Pharmaceuticals' mailing address is 620 Memorial Drive Suite300, CAMBRIDGE MA, 02139. The company can be reached via phone at 617-744-1340 or via email at [email protected]


MarketBeat Community Rating for Syros Pharmaceuticals (SYRS)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  115 (Vote Outperform)
Underperform Votes:  85 (Vote Underperform)
Total Votes:  200
MarketBeat's community ratings are surveys of what our community members think about Syros Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for Syros Pharmaceuticals (NASDAQ:SYRS)

  (How are Consensus Ratings Calculated?)
Ratings Breakdown: 0 Sell Ratings, 1 Hold Rating, 6 Buy Ratings, 0 Strong Buy Ratings
Consensus Rating:Buy (Score: 2.86)
Consensus Price Target: $26.14 (93.06% upside)

Consensus Price Target History for Syros Pharmaceuticals (NASDAQ:SYRS)

Price Target History for Syros Pharmaceuticals (NASDAQ:SYRS)

Analysts' Ratings History for Syros Pharmaceuticals (NASDAQ:SYRS)

Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
10/31/2017Piper Jaffray CompaniesReiterated RatingOverweight -> Overweight$30.00N/AView Rating Details
10/23/2017Roth CapitalInitiated CoverageNeutral -> Neutral$15.00N/AView Rating Details
9/28/2017JMP SecuritiesUpgradeMarket Perform -> Outperform$33.00HighView Rating Details
8/21/2017CannReiterated RatingBuy$28.00LowView Rating Details
8/10/2017WedbushReiterated RatingOutperform$25.00 -> $22.84MediumView Rating Details
8/9/2017Cowen and CompanyReiterated RatingBuyHighView Rating Details
6/12/2017Oppenheimer Holdings, Inc.Set Price TargetBuy$28.00HighView Rating Details
9/9/2016HC WainwrightReiterated RatingHold$10.00N/AView Rating Details
(Data available from 11/23/2015 forward)

Earnings

Earnings History and Estimates Chart for Syros Pharmaceuticals (NASDAQ:SYRS)

Earnings by Quarter for Syros Pharmaceuticals (NASDAQ:SYRS)

Earnings History by Quarter for Syros Pharmaceuticals (NASDAQ SYRS)

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/8/2017Q3 2017($0.53)($0.53)ViewN/AView Earnings Details
8/9/2017Q2 2017($0.55)($0.52)ViewN/AView Earnings Details
5/15/2017Q1 2017($0.59)($0.49)$1.10 millionViewN/AView Earnings Details
3/20/2017Q4 2016($0.64)($0.47)$0.32 millionViewN/AView Earnings Details
11/14/2016Q316($0.54)($0.65)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Syros Pharmaceuticals (NASDAQ:SYRS)
2017 EPS Consensus Estimate: ($2.10)
2018 EPS Consensus Estimate: ($3.14)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.51)($0.51)($0.51)
Q2 20172($0.60)($0.50)($0.55)
Q3 20172($0.54)($0.52)($0.53)
Q4 20172($0.56)($0.45)($0.51)
Q1 20182($0.88)($0.55)($0.72)
Q2 20182($0.91)($0.64)($0.78)
Q3 20182($0.94)($0.72)($0.83)
Q4 20182($0.97)($0.67)($0.82)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Syros Pharmaceuticals (NASDAQ:SYRS)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Syros Pharmaceuticals (NASDAQ SYRS)

Insider Ownership Percentage: 33.60%
Institutional Ownership Percentage: 55.19%
Insider Trades by Quarter for Syros Pharmaceuticals (NASDAQ:SYRS)
Insider Trades by Quarter for Syros Pharmaceuticals (NASDAQ:SYRS)

Insider Trades by Quarter for Syros Pharmaceuticals (NASDAQ SYRS)

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
10/23/2017Colleen Elizabeth DesimoneInsiderSell550$16.06$8,833.00View SEC Filing  
8/14/2017Richard A YoungDirectorSell3,282$22.00$72,204.00View SEC Filing  
8/7/2017Eric R OlsonInsiderSell2,500$23.59$58,975.00View SEC Filing  
7/25/2017Eric R OlsonInsiderSell12,500$21.85$273,125.00View SEC Filing  
7/25/2017Richard A YoungDirectorSell3,282$22.09$72,499.38View SEC Filing  
7/6/2016Redmile Group, LlcMajor ShareholderBuy432,746$12.50$5,409,325.00View SEC Filing  
7/6/2016Robert NelsenDirectorBuy400,000$12.50$5,000,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Syros Pharmaceuticals (NASDAQ SYRS)

Source:
DateHeadline
Syros Pharmaceuticals, Inc. (SYRS) Given Average Rating of "Buy" by BrokeragesSyros Pharmaceuticals, Inc. (SYRS) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - November 19 at 5:32 PM
Critical Analysis: Syros Pharmaceuticals (SYRS) vs. Kadmon Holdings (KDMN)Critical Analysis: Syros Pharmaceuticals (SYRS) vs. Kadmon Holdings (KDMN)
www.americanbankingnews.com - November 15 at 5:46 PM
Syros Announces Appointment of Jeremy P. Springhorn as Chief Business OfficerSyros Announces Appointment of Jeremy P. Springhorn as Chief Business Officer
finance.yahoo.com - November 14 at 8:26 AM
Syros to Present New Preclinical Data on SY-1365 and on Identification of Potential Drug Targets in Triple Negative Breast Cancer at San Antonio Breast Cancer SymposiumSyros to Present New Preclinical Data on SY-1365 and on Identification of Potential Drug Targets in Triple Negative Breast Cancer at San Antonio Breast Cancer Symposium
finance.yahoo.com - November 14 at 8:26 AM
FY2017 EPS Estimates for Syros Pharmaceuticals, Inc. Raised by Oppenheimer Holdings (SYRS)FY2017 EPS Estimates for Syros Pharmaceuticals, Inc. Raised by Oppenheimer Holdings (SYRS)
www.americanbankingnews.com - November 13 at 2:14 AM
FY2021 EPS Estimates for Syros Pharmaceuticals, Inc. Cut by Oppenheimer Holdings (SYRS)FY2021 EPS Estimates for Syros Pharmaceuticals, Inc. Cut by Oppenheimer Holdings (SYRS)
www.americanbankingnews.com - November 10 at 8:11 PM
Syros Pharmaceuticals, Inc. (SYRS) Releases  Earnings Results, Meets ExpectationsSyros Pharmaceuticals, Inc. (SYRS) Releases Earnings Results, Meets Expectations
www.americanbankingnews.com - November 10 at 4:39 PM
Syros Reports Third Quarter 2017 Financial Results and Highlights Accomplishments and Upcoming MilestonesSyros Reports Third Quarter 2017 Financial Results and Highlights Accomplishments and Upcoming Milestones
finance.yahoo.com - November 9 at 2:19 PM
Syros Pharmaceuticals, Inc. (SYRS) Scheduled to Post Quarterly Earnings on MondaySyros Pharmaceuticals, Inc. (SYRS) Scheduled to Post Quarterly Earnings on Monday
www.americanbankingnews.com - November 6 at 6:26 AM
Critical Review: Cardiome Pharma Corporation (CRME) vs. Syros Pharmaceuticals (SYRS)Critical Review: Cardiome Pharma Corporation (CRME) vs. Syros Pharmaceuticals (SYRS)
www.americanbankingnews.com - November 5 at 9:32 PM
Syros Pharmaceuticals, Inc. – Value Analysis (NASDAQ:SYRS) : November 2, 2017Syros Pharmaceuticals, Inc. – Value Analysis (NASDAQ:SYRS) : November 2, 2017
finance.yahoo.com - November 5 at 5:58 AM
Reviewing Syros Pharmaceuticals (SYRS) & Biogen (BIIB)Reviewing Syros Pharmaceuticals (SYRS) & Biogen (BIIB)
www.americanbankingnews.com - November 5 at 5:26 AM
Syros Pharmaceuticals (SYRS) to Results from Ongoing Phase 2 Clinical Trial of SY-1425 and New Preclinical Data on SY-1365 at ASHSyros Pharmaceuticals (SYRS) to Results from Ongoing Phase 2 Clinical Trial of SY-1425 and New Preclinical Data on SY-1365 at ASH
www.streetinsider.com - November 2 at 9:35 AM
Syros Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : SYRS-US : November 1, 2017Syros Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : SYRS-US : November 1, 2017
finance.yahoo.com - November 1 at 9:30 AM
Syros to Present Initial Clinical Data from Ongoing Phase 2 Clinical Trial of SY-1425 and New Preclinical Data on SY-1365 at ASH Annual MeetingSyros to Present Initial Clinical Data from Ongoing Phase 2 Clinical Trial of SY-1425 and New Preclinical Data on SY-1365 at ASH Annual Meeting
finance.yahoo.com - November 1 at 9:30 AM
Zacks: Analysts Anticipate Syros Pharmaceuticals, Inc. (SYRS) to Announce -$0.53 Earnings Per ShareZacks: Analysts Anticipate Syros Pharmaceuticals, Inc. (SYRS) to Announce -$0.53 Earnings Per Share
www.americanbankingnews.com - October 31 at 7:13 PM
Syros Pharmaceuticals (SYRS) Presents New Preclinical PK and PD Data for SY-1365 at AACR-NCI-EORTC ConferenceSyros Pharmaceuticals (SYRS) Presents New Preclinical PK and PD Data for SY-1365 at AACR-NCI-EORTC Conference
www.streetinsider.com - October 31 at 10:19 AM
Syros Presents New Preclinical PK and PD Data for SY-1365, Its First-in-Class Selective CDK7 Inhibitor, at AACR-NCI-EORTC ConferenceSyros Presents New Preclinical PK and PD Data for SY-1365, Its First-in-Class Selective CDK7 Inhibitor, at AACR-NCI-EORTC Conference
finance.yahoo.com - October 31 at 10:19 AM
Comparing Syros Pharmaceuticals (SYRS) & MediWound (MDWD)Comparing Syros Pharmaceuticals (SYRS) & MediWound (MDWD)
www.americanbankingnews.com - October 27 at 12:16 PM
Syros’ Drug Discovery Research in Immuno-Oncology Highlighted in Oral Presentation at American College of Surgeons Clinical CongressSyros’ Drug Discovery Research in Immuno-Oncology Highlighted in Oral Presentation at American College of Surgeons Clinical Congress
finance.yahoo.com - October 26 at 1:12 PM
Syros Pharmaceuticals, Inc. (SYRS) Receives Average Recommendation of "Buy" from BrokeragesSyros Pharmaceuticals, Inc. (SYRS) Receives Average Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - October 25 at 9:52 PM
Syros Pharmaceuticals, Inc. (SYRS) Now Covered by Roth CapitalSyros Pharmaceuticals, Inc. (SYRS) Now Covered by Roth Capital
www.americanbankingnews.com - October 23 at 11:58 PM
Syros Announces Oral Presentation Highlighting Its Drug Discovery Research in Immuno-Oncology at American College of Surgeons Clinical CongressSyros Announces Oral Presentation Highlighting Its Drug Discovery Research in Immuno-Oncology at American College of Surgeons Clinical Congress
finance.yahoo.com - October 21 at 8:58 AM
Syros to Present New Preclinical PK and PD Data on SY-1365, Its First-in-Class Selective CDK7 Inhibitor, at AACR-NCI-EORTC ConferenceSyros to Present New Preclinical PK and PD Data on SY-1365, Its First-in-Class Selective CDK7 Inhibitor, at AACR-NCI-EORTC Conference
finance.yahoo.com - October 17 at 7:50 AM
-$0.53 Earnings Per Share Expected for Syros Pharmaceuticals, Inc. (SYRS) This Quarter-$0.53 Earnings Per Share Expected for Syros Pharmaceuticals, Inc. (SYRS) This Quarter
www.americanbankingnews.com - October 12 at 8:32 PM
Syros Pharmaceuticals, Inc. (SYRS) Downgraded by Zacks Investment Research to "Sell"Syros Pharmaceuticals, Inc. (SYRS) Downgraded by Zacks Investment Research to "Sell"
www.americanbankingnews.com - October 11 at 7:44 PM
Syros Presents Biomarker Data from Its Ongoing Phase 2 Clinical Trial of SY-1425 in Genomically Defined AML and MDS Patients at ESH Conference on AMLSyros Presents Biomarker Data from Its Ongoing Phase 2 Clinical Trial of SY-1425 in Genomically Defined AML and MDS Patients at ESH Conference on AML
finance.yahoo.com - October 6 at 10:59 AM
Syros to Present Biomarker Data from Ongoing Phase 2 Clinical Trial of SY-1425 at ESH Conference on AMLSyros to Present Biomarker Data from Ongoing Phase 2 Clinical Trial of SY-1425 at ESH Conference on AML
finance.yahoo.com - October 3 at 1:17 PM
Comparing Syros Pharmaceuticals (SYRS) & Kamada (KMDA)Comparing Syros Pharmaceuticals (SYRS) & Kamada (KMDA)
www.americanbankingnews.com - October 3 at 10:56 AM
Syros Pharmaceuticals, Inc. (SYRS) Short Interest UpdateSyros Pharmaceuticals, Inc. (SYRS) Short Interest Update
www.americanbankingnews.com - October 1 at 2:38 AM
Syros Pharmaceuticals, Inc. (SYRS) Receives Consensus Recommendation of "Buy" from AnalystsSyros Pharmaceuticals, Inc. (SYRS) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - September 30 at 8:34 PM
Syros Pharmaceuticals, Inc. (SYRS) Upgraded by JMP Securities to Market OutperformSyros Pharmaceuticals, Inc. (SYRS) Upgraded by JMP Securities to Market Outperform
www.americanbankingnews.com - September 28 at 8:48 AM
Financial Comparison: Syros Pharmaceuticals (SYRS) & Its CompetitorsFinancial Comparison: Syros Pharmaceuticals (SYRS) & Its Competitors
www.americanbankingnews.com - September 28 at 12:34 AM
Alexion Pharmaceuticals (ALXN) vs. Syros Pharmaceuticals (SYRS) Financial ComparisonAlexion Pharmaceuticals (ALXN) vs. Syros Pharmaceuticals (SYRS) Financial Comparison
www.americanbankingnews.com - September 25 at 8:30 PM
Oversold Conditions For Syros Pharmaceuticals (SYRS)Oversold Conditions For Syros Pharmaceuticals (SYRS)
www.thestreet.com - September 12 at 10:35 AM
Oversold Conditions For Syros Pharmaceuticals (SYRS)Oversold Conditions For Syros Pharmaceuticals (SYRS)
www.thestreet.com - September 12 at 10:35 AM
Syros Presents PK and PD Data at ESMO for SY-1425, Its First-in-Class Selective RARα Agonist, in Genomically Defined AML and MDS PatientsSyros Presents PK and PD Data at ESMO for SY-1425, Its First-in-Class Selective RARα Agonist, in Genomically Defined AML and MDS Patients
finance.yahoo.com - September 11 at 7:28 AM
Syros Pharmaceuticals, Inc. (SYRS) Given Average Recommendation of "Buy" by AnalystsSyros Pharmaceuticals, Inc. (SYRS) Given Average Recommendation of "Buy" by Analysts
www.americanbankingnews.com - September 5 at 9:00 PM
 Brokerages Expect Syros Pharmaceuticals, Inc. (SYRS) Will Announce Earnings of -$0.53 Per Share Brokerages Expect Syros Pharmaceuticals, Inc. (SYRS) Will Announce Earnings of -$0.53 Per Share
www.americanbankingnews.com - September 5 at 10:20 AM
Syros Pharmaceuticals to Present at Morgan Stanley 15th Annual Global Healthcare ConferenceSyros Pharmaceuticals to Present at Morgan Stanley 15th Annual Global Healthcare Conference
finance.yahoo.com - September 5 at 9:00 AM
Syros Pharmaceuticals to Present at Morgan Stanley 15th Annual Global Healthcare ConferenceSyros Pharmaceuticals to Present at Morgan Stanley 15th Annual Global Healthcare Conference
finance.yahoo.com - September 5 at 9:00 AM
Syros Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : SYRS-US : September 1, 2017Syros Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : SYRS-US : September 1, 2017
finance.yahoo.com - September 2 at 9:15 AM
Syros to Present PK and PD Data from Ongoing Phase 2 Clinical Trial of SY-1425 at ESMO 2017 CongressSyros to Present PK and PD Data from Ongoing Phase 2 Clinical Trial of SY-1425 at ESMO 2017 Congress
finance.yahoo.com - August 31 at 10:41 AM
BRIEF-Syros receives FDA Orphan drug designation for SY-1425 for treatment of AMLBRIEF-Syros receives FDA Orphan drug designation for SY-1425 for treatment of AML
www.reuters.com - August 23 at 12:16 PM
Syros Pharma Wins Orphan Designation From FDASyros Pharma Wins Orphan Designation From FDA
finance.yahoo.com - August 22 at 7:06 AM
Syros Pharmaceuticals (SYRS) Buy Rating Reiterated at CannSyros Pharmaceuticals' (SYRS) Buy Rating Reiterated at Cann
www.americanbankingnews.com - August 21 at 11:14 AM
Syros Receives FDA Orphan Drug Designation for SY-1425 for Treatment of AMLSyros Receives FDA Orphan Drug Designation for SY-1425 for Treatment of AML
finance.yahoo.com - August 21 at 9:15 AM
-$0.53 EPS Expected for Syros Pharmaceuticals, Inc. (SYRS) This Quarter-$0.53 EPS Expected for Syros Pharmaceuticals, Inc. (SYRS) This Quarter
www.americanbankingnews.com - August 17 at 10:24 PM
Syros Pharmaceuticals, Inc. (SYRS) Director Richard A. Young Sells 3,282 SharesSyros Pharmaceuticals, Inc. (SYRS) Director Richard A. Young Sells 3,282 Shares
www.americanbankingnews.com - August 16 at 9:14 PM
Chiasma (CHMA) versus Syros Pharmaceuticals (SYRS) Head-To-Head ComparisonChiasma (CHMA) versus Syros Pharmaceuticals (SYRS) Head-To-Head Comparison
www.americanbankingnews.com - August 16 at 6:32 PM

Social Media

Financials

Chart

Syros Pharmaceuticals (NASDAQ SYRS) Chart for Thursday, November, 23, 2017
Loading chart…

This page was last updated on 11/23/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.